Cargando…
TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy
Recent advances in understanding the roles of immune checkpoints in allowing tumors to circumvent the immune system have led to successful therapeutic strategies that have fundamentally changed oncology practice. Thus far, immunotherapies against only two checkpoint targets have been approved, CTLA-...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981293/ https://www.ncbi.nlm.nih.gov/pubmed/35379739 http://dx.doi.org/10.1136/jitc-2022-004711 |